Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective neuropathologic analysis of adult spinal tumors in a single neuroscience center 2018 - 2023.

Clinical neuropathology·2026
Same author

Handwriting patterns in isolated rapid eye movement sleep behaviour disorder.

Journal of Parkinson's disease·2026
Same author

Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.

Movement disorders clinical practice·2025
Same author

'Pathology is disease' Parkinson's mythology: The 'brain-first-body-first' case study.

Journal of Parkinson's disease·2025
Same author

Neuro-Ophthalmological Manifestations of Episodic Ataxia Type 2 Due to a Novel CACNA1A Mutation.

Movement disorders clinical practice·2025
Same author

N6-methyladenosine (m6A) dysregulation contributes to network excitability in temporal lobe epilepsy.

JCI insight·2025
Same journal

Football-Specific On-Pitch Concussion Assessment Protocol-International Consensus Recommendations.

JAMA neurology·2026
Same journal

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.

JAMA neurology·2026
Same journal

Diminishing Returns of Novel Autoantibody Discovery in Encephalitis.

JAMA neurology·2026
Same journal

Superficial Siderosis and a Spinal Cord Cleft.

JAMA neurology·2026
Same journal

In Defense of Novel Autoantibody Discovery.

JAMA neurology·2026
Same journal

Reversible Bilateral Hypoglossal Palsy With Tongue Atrophy in Isolated Peripheral Nerve Vasculitis.

JAMA neurology·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Parkin disease: a clinicopathologic entity?

Karen M Doherty1, Laura Silveira-Moriyama, Laura Parkkinen

  • 1Reta Lila Weston Institute for Neurological Studies, University College London, London, England.

JAMA Neurology
|March 6, 2013
PubMed
Summary
This summary is machine-generated.

Parkin disease, caused by PARK2 mutations, shows severe neuronal loss in the substantia nigra, similar to Parkinson disease (PD), but with distinct neuropathologic features. This suggests parkin disease is a separate clinicopathologic entity from PD.

More Related Videos

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

Related Experiment Videos

Last Updated: May 13, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

Area of Science:

  • Neurology
  • Genetics
  • Pathology

Background:

  • Mutations in the parkin (PARK2) gene are a leading cause of early-onset parkinsonism.
  • Neuropathologic studies suggest severe substantia nigra neuronal loss in parkin mutations.

Purpose of the Study:

  • To ascertain if parkin-linked parkinsonism represents a distinct clinicopathologic entity compared to Parkinson disease (PD).

Main Methods:

  • Clinical, genetic, and neuropathologic data from 5 unrelated parkin disease cases were analyzed.
  • These cases were compared to 5 pathologically confirmed PD cases and 4 control subjects, matched for age and disease duration.

Main Results:

  • Parkin disease cases presented with tremor and dystonia, with onset around age 34; late features included gait freezing and motor fluctuations.
  • Neuronal loss in the substantia nigra was severe, comparable to PD, but with relative preservation of the dorsal tier.
  • Mild loss was noted in the locus coeruleus and dorsal motor nucleus of the vagus; Lewy bodies were sparse or absent.

Conclusions:

  • Parkin disease exhibits a more restricted morphologic abnormality than PD, primarily ventral nigral degeneration.
  • The neuropathologic findings support parkin disease as a distinct entity from Parkinson disease.